Target Cancer Centers NeuralFrame already collaborates with NCI designated Cancer Centers and is Platinum Sponsor of the NCRA conference, signaling access to cancer registrars and center decision makers. This positions the company to expand its footprint across more centers and registry networks by offering its KACI Intelligence platform to standardize and accelerate data workflows for oncology research and drug development.

Accelerated Trials KACI Intelligence automates structuring, coding, and summarizing patient data from EHRs, reconstructing treatment timelines and normalizing biomarkers across institutions. This capability presents a clear value proposition to pharma and CROs seeking faster cohort identification and real world evidence generation without heavy manual chart abstraction.

Interoperability Opportunity The platform already integrates diverse data types including pathology, labs, imaging, medications, and biomarkers, suggesting an interoperability driven selling opportunity with health systems, cancer centers, and EHR vendors seeking unified oncology data pipelines.

Real Time Research NeuralFrame's emphasis on real time clinical data turned into trusted infrastructure supports near real time discovery, tracking of outcomes, and adaptive study designs. This can be marketed to pharma and life sciences partners looking to shorten development cycles and improve regulatory readiness.

Scalable Services As a mid sized player with a lean team, NeuralFrame can monetize scalable professional services onboarding, data governance, and ongoing support to accelerate deployments across sites. Building scalable services and governance frameworks could unlock recurring revenue from multi site oncology programs and global collaborations.